Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neoplasm Metastasis × lorlatinib × Clear all

Phase

Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 10 Lung Neoplasms 4 Non Small Cell Lung Cancer Metastatic 3 Neoplasms 2 Recurrence 1 Neoplasm Metastasis 1 Neoadjuvant Non-Small Cell Lung Cancer 1 Lymphoma, Large-Cell, Anaplastic 1 Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer 1 Advanced Non-Small Cell Lung Cancer 1 ALK Positive Non-small Cell Lung Cancer 1

Interventions

Oxaliplatin 67 Capecitabine 60 Fluorouracil 58 Bevacizumab 54 Gemcitabine 51 Paclitaxel 50 Leucovorin 50 Irinotecan 40 Docetaxel 39 Carboplatin 39 Cisplatin 38 pembrolizumab 37 Nivolumab 36 Cetuximab 35 Sunitinib 25 Trastuzumab 24 Radiosurgery 24 Radiotherapy 21 Doxorubicin 21 Cyclophosphamide 21 Panitumumab 20 Drug Therapy 19 Pemetrexed 18 Everolimus 18 Sorafenib 17 Interleukin-2 16 Fulvestrant 16 Albumin-Bound Paclitaxel 16 atezolizumab 15 Erlotinib Hydrochloride 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05948462 2023-12-13

NSCLC

SCRI Development Innovations, LLC

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡